-
Je něco špatně v tomto záznamu ?
PRDM1 rs2185379, unlike BRCA1, is not a prognostic marker in patients with advanced ovarian cancer
K. Horackova, M. Vocka, S. Lopatova, P. Zemankova, Z. Kleibl, J. Soukupova
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
PubMed
38607753
DOI
10.3233/cbm-230358
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- genotyp MeSH
- jednonukleotidový polymorfismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery * genetika MeSH
- nádory vaječníků * genetika mortalita patologie MeSH
- prognóza MeSH
- protein BRCA1 * genetika MeSH
- protein PRDI-BF1 * genetika MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Ovarian cancer (OC) is mostly diagnosed in advanced stages with high incidence-to-mortality rate. Nevertheless, some patients achieve long-term disease-free survival. However, the prognostic markers have not been well established. OBJECTIVE: The primary objective of this study was to analyse the association of the suggested prognostic marker rs2185379 in PRDM1 with long-term survival in a large independent cohort of advanced OC patients. METHODS: We genotyped 545 well-characterized advanced OC patients. All patients were tested for OC predisposition. The effect of PRDM1 rs2185379 and other monitored clinicopathological and genetic variables on survival were analysed. RESULTS: The univariate analysis revealed no significant effect of PRDM1 rs2185379 on survival whereas significantly worse prognosis was observed in postmenopausal patients (HR = 2.49; 95%CI 1.90-3.26; p= 4.14 × 10 - 11) with mortality linearly increasing with age (HR = 1.05 per year; 95%CI 1.04-1.07; p= 2 × 10 - 6), in patients diagnosed with non-high-grade serous OC (HR = 0.44; 95%CI 0.32-0.60; p= 1.95 × 10 - 7) and in patients carrying a gBRCA1 pathogenic variant (HR = 0.65; 95%CI 0.48-0.87; p= 4.53 × 10 - 3). The multivariate analysis interrogating the effect of PRDM1 rs2185379 with other significant prognostic factors revealed marginal association of PRDM1 rs2185379 with worse survival in postmenopausal women (HR = 1.54; 95%CI 1.01-2.38; p= 0.046). CONCLUSIONS: Unlike age at diagnosis, OC histology or gBRCA1 status, rs2185379 in PRDM1 is unlikely a marker of long-term survival in patients with advance OC.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014591
- 003
- CZ-PrNML
- 005
- 20240905134115.0
- 007
- ta
- 008
- 240725s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3233/CBM-230358 $2 doi
- 035 __
- $a (PubMed)38607753
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Horackova, Klara $u First Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 245 10
- $a PRDM1 rs2185379, unlike BRCA1, is not a prognostic marker in patients with advanced ovarian cancer / $c K. Horackova, M. Vocka, S. Lopatova, P. Zemankova, Z. Kleibl, J. Soukupova
- 520 9_
- $a BACKGROUND: Ovarian cancer (OC) is mostly diagnosed in advanced stages with high incidence-to-mortality rate. Nevertheless, some patients achieve long-term disease-free survival. However, the prognostic markers have not been well established. OBJECTIVE: The primary objective of this study was to analyse the association of the suggested prognostic marker rs2185379 in PRDM1 with long-term survival in a large independent cohort of advanced OC patients. METHODS: We genotyped 545 well-characterized advanced OC patients. All patients were tested for OC predisposition. The effect of PRDM1 rs2185379 and other monitored clinicopathological and genetic variables on survival were analysed. RESULTS: The univariate analysis revealed no significant effect of PRDM1 rs2185379 on survival whereas significantly worse prognosis was observed in postmenopausal patients (HR = 2.49; 95%CI 1.90-3.26; p= 4.14 × 10 - 11) with mortality linearly increasing with age (HR = 1.05 per year; 95%CI 1.04-1.07; p= 2 × 10 - 6), in patients diagnosed with non-high-grade serous OC (HR = 0.44; 95%CI 0.32-0.60; p= 1.95 × 10 - 7) and in patients carrying a gBRCA1 pathogenic variant (HR = 0.65; 95%CI 0.48-0.87; p= 4.53 × 10 - 3). The multivariate analysis interrogating the effect of PRDM1 rs2185379 with other significant prognostic factors revealed marginal association of PRDM1 rs2185379 with worse survival in postmenopausal women (HR = 1.54; 95%CI 1.01-2.38; p= 0.046). CONCLUSIONS: Unlike age at diagnosis, OC histology or gBRCA1 status, rs2185379 in PRDM1 is unlikely a marker of long-term survival in patients with advance OC.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nádory vaječníků $x genetika $x mortalita $x patologie $7 D010051
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a nádorové biomarkery $x genetika $7 D014408
- 650 12
- $a protein PRDI-BF1 $x genetika $7 D000074462
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a protein BRCA1 $x genetika $7 D019313
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a jednonukleotidový polymorfismus $7 D020641
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a genotyp $7 D005838
- 650 _2
- $a senioři nad 80 let $7 D000369
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vocka, Michal $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Lopatova, Sarka $u First Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Zemankova, Petra $u First Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Institute of Pathological Physiology, First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Kleibl, Zdenek $u First Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Institute of Pathological Physiology, First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Soukupova, Jana $u First Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 773 0_
- $w MED00173146 $t Disease markers. Section A, Cancer Biomarkers $x 1875-8592 $g Roč. 40, č. 2 (2024), s. 199-203
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38607753 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134108 $b ABA008
- 999 __
- $a ok $b bmc $g 2144012 $s 1226457
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 40 $c 2 $d 199-203 $e - $i 1875-8592 $m Disease markers. Section A, Cancer Biomarkers $n Cancer Biomark $x MED00173146
- LZP __
- $a Pubmed-20240725
